In a bid to capitalize on the increasing prevalence of cannabis consumption in the US, pharmaceutical companies have introduced a new pill that claims to combat marijuana addiction. The experimental drug, AEF-0117, has shown promise in a small trial by reducing the addictive impact of THC, the primary psychoactive compound in cannabis. While the study published in the journal Nature Medicine may appear encouraging at first glance, a closer examination raises several concerns about the motives behind such pharmaceutical interventions.
Jowell & Randy member Randy is expanding into cannabis with La Zaza, a brand built…
wo of the most popular autoflowering takes on the Cookies family are Auto Girl Scout…
Jamaica has introduced two new special permits designed to help traditional growers and small farmers…
Italy has extensive opioid use, established illicit drug markets and criminal organizations capable of moving…
A strange prophecy sends an isolated artist on a three-day collision with grief, love, creativity,…
Yasquasia Delcarmen was remanded into custody the day her federal sentence came down. Her son…